Article
Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2017
Lohavanichbutr Pawadee, Sakoda Lori C, Amos Christopher I, Arnold Susanne M, Christiani David C, Davies Michael P A, Field John K, Haura Eric B, Hung Rayjean J, Kohno Takashi, Landi Maria Teresa, Liu Geoffrey, Liu Yi, Marcus Michael W, O'Kane Grainne M, Schabath Matthew B, Shiraishi Kouya, Slone Stacey A, Tardón Adonina, Yang Ping, Yoshida Kazushi, Zhang Ruyang, Zong Xuchen, Goodman Gary E, Weiss Noel S, Chen Chu
Abstract excerpt
Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients.Experimental Design: Two TDP1 SNPs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
